SNDRIs are so-called triple reuptake inhibitors, which elevate extracellular plasma concentrations of all three monoamine neurotransmitters, serotonin, norepinephrine and dopamine in the synaptic cleft. These compounds show high potency but low selectivity between the different monoamine transporter proteins. No SNDRIs are yet on the market, although the first of these agents tesofensine is currently in clinical trials, and other compounds such as brasofensine and GlaxoSmithKline's NS2359 are under development.
It should be noted that some SNRI drugs such as Venlafaxine (Effexor) and Sibutramine (Meridia/Reductil) are known to weakly inhibit the reuptake of dopamine at high doses, and so while these drugs are selective for the serotonin and noradrenaline transporters at normal doses, they can start to act as SNDRIs when taken at doses above the normal therapeutic range.
Allyl-containing sulfides in garlic increase uncoupling protein content in brown adipose tissue, and noradrenaline and adrenaline secretion in rats
Feb 01, 1999; Allyl-Containing Sulfides in Garlic Increase Uncoupling Protein Content in Brown Adipose Tissue, and noradrenaline and...